PAVmed (PAVM) Research & Development (2015 - 2025)

PAVmed's Research & Development history runs 11 years deep, the most recent figure standing at -$1.7 million for Q4 2025.

• On a quarterly basis, Research & Development fell 316.48% year-over-year to -$1.7 million in Q4 2025; TTM through Dec 2025 was $31000.0, a 99.77% decrease from a year earlier, with the FY2025 full-year figure at $917000.0, down 84.54% from the prior year.
• Research & Development eased to -$1.7 million in Q4 2025 per PAVM's latest filing, from $201000.0 in the prior quarter.
• Across five years, Research & Development topped out at $11.8 million in Q4 2022 and bottomed at -$4.0 million in Q4 2021.
• The 5-year median for Research & Development is $3.3 million (2021), against an average of $3.0 million.
• Across the five-year window, Research & Development soared 395.73% in 2022 and slumped 316.48% in 2025, its largest moves.
• Year by year, Research & Development stood at -$4.0 million in 2021, then surged by 395.73% to $11.8 million in 2022, then tumbled by 41.4% to $6.9 million in 2023, then tumbled by 88.31% to $807000.0 in 2024, then slumped by 316.48% to -$1.7 million in 2025.
• Per Business Quant, the three latest PAVM Research & Development figures stand at -$1.7 million (Q4 2025), $201000.0 (Q3 2025), and $790000.0 (Q2 2025).